1
|
Li F, Zhi J, Zhao R, Sun Y, Wen H, Cai H, Chen W, Jiang X, Bai R. Discovery of matrix metalloproteinase inhibitors as anti-skin photoaging agents. Eur J Med Chem 2024; 267:116152. [PMID: 38278079 DOI: 10.1016/j.ejmech.2024.116152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2023] [Accepted: 01/11/2024] [Indexed: 01/28/2024]
Abstract
Photodamage is the result of prolonged exposure of the skin to sunlight. This exposure causes an overexpression of matrix metalloproteinases (MMPs), leading to the abnormal degradation of collagen in the skin tissue and resulting in skin aging and damage. This review presents a detailed overview of MMPs as a potential target for addressing skin aging. Specifically, we elucidated the precise mechanisms by which MMP inhibitors exert their anti-photoaging effects. Furthermore, we comprehensively analyzed the current research progress on MMP inhibitors that demonstrate significant inhibitory activity against MMPs and anti-skin photoaging effects. The review also provides insights into the structure-activity relationships of these inhibitors. Our objective in conducting this review is to provide valuable practical information to researchers engaged in investigations on anti-skin photoaging.
Collapse
Affiliation(s)
- Feifan Li
- School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, PR China; Key Laboratory of Elemene Class Anti-tumor Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, 311121, PR China
| | - Jia Zhi
- School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, PR China; Key Laboratory of Elemene Class Anti-tumor Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, 311121, PR China
| | - Rui Zhao
- School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, PR China; Key Laboratory of Elemene Class Anti-tumor Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, 311121, PR China
| | - Yinyan Sun
- School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, PR China; Key Laboratory of Elemene Class Anti-tumor Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, 311121, PR China
| | - Hao Wen
- School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, PR China; Key Laboratory of Elemene Class Anti-tumor Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, 311121, PR China
| | - Hong Cai
- School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, PR China; Key Laboratory of Elemene Class Anti-tumor Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, 311121, PR China
| | - Wenchao Chen
- School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, PR China; Key Laboratory of Elemene Class Anti-tumor Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, 311121, PR China
| | - Xiaoying Jiang
- School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, PR China; Key Laboratory of Elemene Class Anti-tumor Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, 311121, PR China
| | - Renren Bai
- School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, PR China; Key Laboratory of Elemene Class Anti-tumor Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, 311121, PR China.
| |
Collapse
|
2
|
Knapinska AM, Singh C, Drotleff G, Blanco D, Chai C, Schwab J, Herd A, Fields GB. Matrix Metalloproteinase 13 Inhibitors for Modulation of Osteoclastogenesis: Enhancement of Solubility and Stability. ChemMedChem 2021; 16:1133-1142. [PMID: 33331147 PMCID: PMC8035250 DOI: 10.1002/cmdc.202000911] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2020] [Revised: 12/14/2020] [Indexed: 11/08/2022]
Abstract
Matrix metalloproteinase 13 (MMP-13) activity has been correlated to breast cancer bone metastasis. It has been proposed that MMP-13 contributes to bone metastasis through the promotion of osteoclastogenesis. To explore the mechanisms of MMP-13 action, we previously described a highly efficacious and selective MMP-13 inhibitor, RF036. Unfortunately, further pursuit of RF036 as a probe of MMP-13 in vitro and in vivo activities was not practical due to the limited solubility and stability of the inhibitor. Our new study has explored replacing the RF036 backbone sulfur atom and terminal methyl group to create inhibitors with more favorable pharmacokinetic properties. One compound, designated inhibitor 3, in which the backbone sulfur and terminal methyl group of RF036 were replaced by nitrogen and oxetane, respectively, had comparable activity, selectivity, and membrane permeability to RF036, while exhibiting greatly enhanced solubility and stability. Inhibitor 3 effectively inhibited MMP-13-mediated osteoclastogenesis but spared collagenolysis, and thus represents a next-generation MMP-13 probe applicable for in vivo studies of breast cancer metastasis.
Collapse
Affiliation(s)
- Anna M Knapinska
- Department of Chemistry & Biochemistry, Florida Atlantic University, 5353 Parkside Drive, Jupiter, FL 33458, USA
- Institute for Human Health & Disease Intervention (I-HEALTH), Florida Atlantic University, 5353 Parkside Drive, Jupiter, FL 33458, USA
| | - Chandani Singh
- Department of Chemistry & Biochemistry, Florida Atlantic University, 5353 Parkside Drive, Jupiter, FL 33458, USA
- Institute for Human Health & Disease Intervention (I-HEALTH), Florida Atlantic University, 5353 Parkside Drive, Jupiter, FL 33458, USA
| | - Gary Drotleff
- Department of Biological Sciences, Florida Atlantic University, 777 Glades Road, Boca Raton, FL 33431, USA
| | - Daniela Blanco
- Institute for Human Health & Disease Intervention (I-HEALTH), Florida Atlantic University, 5353 Parkside Drive, Jupiter, FL 33458, USA
| | - Cedric Chai
- Department of Biological Sciences, Florida Atlantic University, 777 Glades Road, Boca Raton, FL 33431, USA
| | - Jason Schwab
- Institute for Human Health & Disease Intervention (I-HEALTH), Florida Atlantic University, 5353 Parkside Drive, Jupiter, FL 33458, USA
| | - Anu Herd
- Institute for Human Health & Disease Intervention (I-HEALTH), Florida Atlantic University, 5353 Parkside Drive, Jupiter, FL 33458, USA
| | - Gregg B Fields
- Department of Chemistry & Biochemistry, Florida Atlantic University, 5353 Parkside Drive, Jupiter, FL 33458, USA
- Institute for Human Health & Disease Intervention (I-HEALTH), Florida Atlantic University, 5353 Parkside Drive, Jupiter, FL 33458, USA
- Department of Chemistry, The Scripps Research Institute/Scripps Florida, 120 Scripps Way, Jupiter, FL 33458, USA
| |
Collapse
|
3
|
Fischer T, Riedl R. Challenges with matrix metalloproteinase inhibition and future drug discovery avenues. Expert Opin Drug Discov 2020; 16:75-88. [PMID: 32921161 DOI: 10.1080/17460441.2020.1819235] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
INTRODUCTION Matrix metalloproteinases have been in the scope of pharmaceutical drug discovery for decades as promising targets for drug development. Until present, no modulator of the enzyme class survived clinical trials, all failing for various reasons. Nevertheless, the target family did not lose its attractiveness and there is ever more evidence that MMP modulators are likely to overcome the hurdles and result in successful clinical therapies. AREAS COVERED This review provides an overview of past efforts that were taken in the development of MMP inhibitors and insight into promising strategies that might enable drug discovery in the field in the future. Small molecule inhibitors as well as biomolecules are reviewed. EXPERT OPINION Despite the lack of successful clinical trials in the past, there is ongoing research in the field of MMP modulation, proving the target class has not lost its appeal to pharmaceutical research. With ever-growing insights from different scientific fields that shed light on previously unknown correlations, it is now time to use synergies deriving from biological knowledge, chemical structure generation, and clinical application to reach the ultimate goal of bringing MMP derived drugs on a broad front for the benefit of patients into therapeutic use.
Collapse
Affiliation(s)
- Thomas Fischer
- Center of Organic and Medicinal Chemistry, Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences ZHAW , 8820 Wädenswil, Switzerland
| | - Rainer Riedl
- Center of Organic and Medicinal Chemistry, Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences ZHAW , 8820 Wädenswil, Switzerland
| |
Collapse
|
4
|
Structure-based design and optimization of pyrimidine- and 1,2,4-triazolo[4,3-a]pyrimidine-based matrix metalloproteinase-10/13 inhibitors via Dimroth rearrangement towards targeted polypharmacology. Bioorg Chem 2020; 96:103616. [DOI: 10.1016/j.bioorg.2020.103616] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2019] [Revised: 01/20/2020] [Accepted: 01/22/2020] [Indexed: 11/15/2022]
|
5
|
Abstract
Introduction: The development of drug candidates with a defined selectivity profile and a unique molecular structure is of fundamental interest for drug discovery. In contrast to the costly screening of large substance libraries, the targeted de novo design of a drug by using structural information of either the biological target and/or structure-activity relationship data of active modulators offers an efficient and intellectually appealing alternative. Areas covered: This review provides an overview on the different techniques of de novo drug design (ligand-based drug design, structure-based drug design, and fragment-based drug design) and highlights successful examples of this targeted approach toward selective modulators of therapeutically relevant targets. Expert opinion: De novo drug design has established itself as a very efficient method for the development of potent and selective modulators for a variety of different biological target classes. The ever-growing wealth of structural data on therapeutic targets will certainly further enhance the importance of de novo design for the drug discovery process in the future. However, a consistent use of the terminology of de novo drug design in the scientific literature should be sought.
Collapse
Affiliation(s)
- Thomas Fischer
- a Center of Organic and Medicinal Chemistry, Institute of Chemistry and Biotechnology , Zurich University of Applied Sciences ZHAW , Wädenswil , Switzerland
| | - Silvia Gazzola
- b Dipartimento di Scienza e Alta Tecnologia , Università degli Studi dell'Insubria , Como , Italy
| | - Rainer Riedl
- a Center of Organic and Medicinal Chemistry, Institute of Chemistry and Biotechnology , Zurich University of Applied Sciences ZHAW , Wädenswil , Switzerland
| |
Collapse
|
6
|
Fischer T, Senn N, Riedl R. Design and Structural Evolution of Matrix Metalloproteinase Inhibitors. Chemistry 2019; 25:7960-7980. [DOI: 10.1002/chem.201805361] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2018] [Revised: 01/09/2019] [Indexed: 12/15/2022]
Affiliation(s)
- Thomas Fischer
- Center of Organic and Medicinal Chemistry, Institute of Chemistry, and BiotechnologyZurich University of Applied Sciences (ZHAW) Einsiedlerstrasse 31 8820 Wädenswil Switzerland
| | - Nicole Senn
- Center of Organic and Medicinal Chemistry, Institute of Chemistry, and BiotechnologyZurich University of Applied Sciences (ZHAW) Einsiedlerstrasse 31 8820 Wädenswil Switzerland
| | - Rainer Riedl
- Center of Organic and Medicinal Chemistry, Institute of Chemistry, and BiotechnologyZurich University of Applied Sciences (ZHAW) Einsiedlerstrasse 31 8820 Wädenswil Switzerland
| |
Collapse
|
7
|
High Consistency of Structure-Based Design and X-Ray Crystallography: Design, Synthesis, Kinetic Evaluation and Crystallographic Binding Mode Determination of Biphenyl- N-acyl-β-d-Glucopyranosylamines as Glycogen Phosphorylase Inhibitors. Molecules 2019; 24:molecules24071322. [PMID: 30987252 PMCID: PMC6479789 DOI: 10.3390/molecules24071322] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2019] [Revised: 03/30/2019] [Accepted: 04/01/2019] [Indexed: 11/17/2022] Open
Abstract
Structure-based design and synthesis of two biphenyl-N-acyl-β-d-glucopyranosylamine derivatives as well as their assessment as inhibitors of human liver glycogen phosphorylase (hlGPa, a pharmaceutical target for type 2 diabetes) is presented. X-ray crystallography revealed the importance of structural water molecules and that the inhibitory efficacy correlates with the degree of disturbance caused by the inhibitor binding to a loop crucial for the catalytic mechanism. The in silico-derived models of the binding mode generated during the design process corresponded very well with the crystallographic data.
Collapse
|
8
|
Gall FM, Hohl D, Frasson D, Wermelinger T, Mittl PRE, Sievers M, Riedl R. Von der Natur inspiriertes Wirkstoffdesign: kristallographische Detektion eines selbstgenerierten Inhibitor‐Grundgerüsts. Angew Chem Int Ed Engl 2019. [DOI: 10.1002/ange.201812348] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Flavio M. Gall
- Institut für Chemie und BiotechnologieFachgruppe Organische Chemie und MedizinalchemieZHAW Zürcher Hochschule für Angewandte Wissenschaften Einsiedlerstrasse 31 8820 Wädenswil Schweiz
| | - Deborah Hohl
- Institut für Chemie und BiotechnologieFachgruppe Organische Chemie und MedizinalchemieZHAW Zürcher Hochschule für Angewandte Wissenschaften Einsiedlerstrasse 31 8820 Wädenswil Schweiz
| | - David Frasson
- Institut für Chemie und Biotechnologie, Fachgruppe MolekularbiologieZHAW Zürcher Hochschule für Angewandte Wissenschaften Einsiedlerstrasse 31 8820 Wädenswil Schweiz
| | - Tobias Wermelinger
- Institut für Chemie und Biotechnologie, Fachgruppe MolekularbiologieZHAW Zürcher Hochschule für Angewandte Wissenschaften Einsiedlerstrasse 31 8820 Wädenswil Schweiz
| | - Peer R. E. Mittl
- Biochemisches InstitutUniversität Zürich Winterthurerstrasse 190 8057 Zürich Schweiz
| | - Martin Sievers
- Institut für Chemie und Biotechnologie, Fachgruppe MolekularbiologieZHAW Zürcher Hochschule für Angewandte Wissenschaften Einsiedlerstrasse 31 8820 Wädenswil Schweiz
| | - Rainer Riedl
- Institut für Chemie und BiotechnologieFachgruppe Organische Chemie und MedizinalchemieZHAW Zürcher Hochschule für Angewandte Wissenschaften Einsiedlerstrasse 31 8820 Wädenswil Schweiz
| |
Collapse
|
9
|
Gall FM, Hohl D, Frasson D, Wermelinger T, Mittl PRE, Sievers M, Riedl R. Drug Design Inspired by Nature: Crystallographic Detection of an Auto‐Tailored Protease Inhibitor Template. Angew Chem Int Ed Engl 2019; 58:4051-4055. [DOI: 10.1002/anie.201812348] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2018] [Revised: 12/07/2018] [Indexed: 12/31/2022]
Affiliation(s)
- Flavio M. Gall
- Institute of Chemistry and BiotechnologyCenter of Organic and Medicinal ChemistryZHAW Zurich University of Applied Sciences Einsiedlerstrasse 31 8820 Wädenswil Switzerland
| | - Deborah Hohl
- Institute of Chemistry and BiotechnologyCenter of Organic and Medicinal ChemistryZHAW Zurich University of Applied Sciences Einsiedlerstrasse 31 8820 Wädenswil Switzerland
| | - David Frasson
- Institute of Chemistry and BiotechnologyCenter of Molecular BiologyZHAW Zurich University of Applied Sciences Einsiedlerstrasse 31 8820 Wädenswil Switzerland
| | - Tobias Wermelinger
- Institute of Chemistry and BiotechnologyCenter of Molecular BiologyZHAW Zurich University of Applied Sciences Einsiedlerstrasse 31 8820 Wädenswil Switzerland
| | - Peer R. E. Mittl
- Department of BiochemistryUniversity of Zurich Winterthurerstrasse 190 8057 Zürich Switzerland
| | - Martin Sievers
- Institute of Chemistry and BiotechnologyCenter of Molecular BiologyZHAW Zurich University of Applied Sciences Einsiedlerstrasse 31 8820 Wädenswil Switzerland
| | - Rainer Riedl
- Institute of Chemistry and BiotechnologyCenter of Organic and Medicinal ChemistryZHAW Zurich University of Applied Sciences Einsiedlerstrasse 31 8820 Wädenswil Switzerland
| |
Collapse
|
10
|
Argudo PG, Carril M, Martín-Romero MT, Giner-Casares JJ, Carrillo-Carrión C. Surface-Active Fluorinated Quantum Dots for Enhanced Cellular Uptake. Chemistry 2018; 25:195-199. [PMID: 30257052 DOI: 10.1002/chem.201804704] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2018] [Indexed: 12/28/2022]
Abstract
Fluorescent nanoparticles, such as quantum dots, hold great potential for biomedical applications, mainly sensing and bioimaging. However, the inefficient cell uptake of some nanoparticles hampers their application in clinical practice. Here, the effect of the modification of the quantum dot surface with fluorinated ligands to increase their surface activity and, thus, enhance their cellular uptake was explored.
Collapse
Affiliation(s)
- Pablo G Argudo
- Institute of Fine Chemistry and Nanochemistry, Department of Physical Chemistry and Applied Thermodynamics, University of Córdoba, Campus de Rabanales, Edificio Marie Curie, 14014, Córdoba, Spain
| | - Mónica Carril
- Biofisika Institute (CSIC, UPV/EHU) and Department of Biochemistry and Molecular Biology, University of the Basque Country UPV/EHU, Barrio Sarriena s/n, 48940, Leioa, Spain.,Ikerbasque, Basque Foundation for Science, Maria Diaz de Haro 3,6 solaiura, 48011, Bilbao, Spain
| | - María T Martín-Romero
- Institute of Fine Chemistry and Nanochemistry, Department of Physical Chemistry and Applied Thermodynamics, University of Córdoba, Campus de Rabanales, Edificio Marie Curie, 14014, Córdoba, Spain
| | - Juan J Giner-Casares
- Institute of Fine Chemistry and Nanochemistry, Department of Physical Chemistry and Applied Thermodynamics, University of Córdoba, Campus de Rabanales, Edificio Marie Curie, 14014, Córdoba, Spain
| | - Carolina Carrillo-Carrión
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Paseo Miramón 182, 20014, San Sebastian, Spain.,Center for Research in Biological Chemistry and Molecular Materials (CiQUS), University of Santiago de Compostela, Jenaro de la Fuente s/n, 15782, Santiago de Compostela, Spain
| |
Collapse
|
11
|
Senn N, Ott M, Lanz J, Riedl R. Targeted Polypharmacology: Discovery of a Highly Potent Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-10/-13 Inhibitor. J Med Chem 2017; 60:9585-9598. [DOI: 10.1021/acs.jmedchem.7b01001] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Nicole Senn
- Institute of Chemistry and
Biotechnology, Center for Organic and Medicinal Chemistry, ZHAW Zurich University of Applied Sciences, Einsiedlerstrasse 31, 8820 Wädenswil, Switzerland
| | - Michael Ott
- Institute of Chemistry and
Biotechnology, Center for Organic and Medicinal Chemistry, ZHAW Zurich University of Applied Sciences, Einsiedlerstrasse 31, 8820 Wädenswil, Switzerland
| | - Jan Lanz
- Institute of Chemistry and
Biotechnology, Center for Organic and Medicinal Chemistry, ZHAW Zurich University of Applied Sciences, Einsiedlerstrasse 31, 8820 Wädenswil, Switzerland
| | - Rainer Riedl
- Institute of Chemistry and
Biotechnology, Center for Organic and Medicinal Chemistry, ZHAW Zurich University of Applied Sciences, Einsiedlerstrasse 31, 8820 Wädenswil, Switzerland
| |
Collapse
|
12
|
Development of a Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-7/-13 Inhibitor. Molecules 2017; 22:molecules22091548. [PMID: 32961647 PMCID: PMC6151531 DOI: 10.3390/molecules22091548] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2017] [Revised: 09/08/2017] [Accepted: 09/08/2017] [Indexed: 12/12/2022] Open
Abstract
Matrix metalloproteinase 7 (MMP-7) is a member of the MMP superfamily and is able to degrade extracellular matrix proteins such as casein, gelatin, fibronectin and proteoglycan. MMP-7 is a validated target for the development of small molecule drugs against cancer. MMP-13 is within the enzyme class the most efficient contributor to type II collagen degeneration and is a validated target in arthritis and cancer. We have developed the dual MMP-7/-13 inhibitor ZHAWOC6941 with IC50-values of 2.2 μM (MMP-7) and 1.2 μM (MMP-13) that is selective over a broad range of MMP isoforms. It spares MMP-1, -2, -3, -8, -9, -12 and -14, making it a valuable modulator for targeted polypharmacology approaches.
Collapse
|
13
|
Fischer T, Riedl R. Targeted Fluoro Positioning for the Discovery of a Potent and Highly Selective Matrix Metalloproteinase Inhibitor. ChemistryOpen 2017; 6:192-195. [PMID: 28413749 PMCID: PMC5390795 DOI: 10.1002/open.201600158] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2016] [Indexed: 12/28/2022] Open
Abstract
The incorporation of fluorine atoms into functional molecules is of wide interest in synthetic organic chemistry as well as cognate disciplines. In particular, in medicinal chemistry, there is a strong desire to positively influence the physicochemical molecular properties of drug compounds by introducing fluorine into biologically active molecules. Here, we present targeted fluoro positioning as the key design principle of converting a weak matrix metalloproteinase‐13 (MMP‐13) inhibitor into a very potent (IC50=6 nm) and highly selective (selectivity factors of >1000 over MMP‐1, 2, 3, 7, 8, 9, 10, 12, 14) inhibitor with excellent plasma and microsomal stability, and no binding to the hERG channel (hERG: human ether‐a‐go‐go related gene).
Collapse
Affiliation(s)
- Thomas Fischer
- Institute of Chemistry and Biotechnology Center for Organic and Medicinal Chemistry Zurich University of Applied Sciences (ZHAW) Einsiedlerstrasse 318820 Wädenswil Switzerland
| | - Rainer Riedl
- Institute of Chemistry and Biotechnology Center for Organic and Medicinal Chemistry Zurich University of Applied Sciences (ZHAW) Einsiedlerstrasse 318820 Wädenswil Switzerland
| |
Collapse
|